These findings underline the role of Bcl-xL protein as a resistance factor in colon cancer and as an attractive target for therapeutic concepts capable of specifically modulating protein expression such as in AS oligonucleotides strategies. This evidence concerns the gene BCL2L1 and colonic neoplasm.